AstraZeneca | AZN
Stock Price
11,046.00
Daily Change
6.00 0.05%
Monthly
5.85%
Yearly
5.66%
Q1 Forecast
11,037.61



Peers Price Chg Day Year Date
AbbVie 170.40 1.19 0.70% 3.76% Jan/23
Alcon AG 80.46 -0.44 -0.54% 21.03% Jan/23
Almirall 8.77 0.32 3.73% 0.40% Jan/23
Amgen 277.78 4.39 1.61% -9.07% Jan/23
argenx SE 618.60 -2.80 -0.45% 83.67% Jan/23
Autolus Therapeutics Ltd 2.27 0.11 4.86% -60.54% Jan/23
AstraZeneca 11,046.00 6.00 0.05% 5.66% Jan/23
Bayer 21.08 0.09 0.43% -35.40% Jan/23
Biogen 143.62 0.89 0.62% -41.89% Jan/23
Bristol-Myers Squibb 59.13 2.03 3.56% 17.70% Jan/23
Fresenius Medical Care 46.61 2.15 4.84% 26.55% Jan/23
Fresenius 36.80 0.89 2.48% 38.50% Jan/23
Genmab 1,512.00 2.00 0.13% -19.85% Jan/23
Gilead Sciences 92.85 -0.15 -0.16% 16.75% Jan/23
Galapagos 22.78 -0.16 -0.70% -35.50% Jan/23
GRIFOLS 8.51 -0.37 -4.14% -10.34% Jan/23
GlaxoSmithKline 1,363.50 8.00 0.59% -12.30% Jan/23
Hikma Pharmaceutical 2,146.00 16.00 0.75% 10.16% Jan/23
Haleon 375.00 3.60 0.97% 19.67% Jan/23
Indivior 959.00 -14.00 -1.44% -31.70% Jan/23
Eli Lilly 765.95 12.67 1.68% 20.87% Jan/23
Lonza 583.20 2.80 0.48% 52.91% Jan/23
Merck 144.40 -0.20 -0.14% -1.67% Jan/23
Merck 96.56 0.88 0.92% -18.78% Jan/23
Novartis 90.26 0.53 0.59% -3.50% Jan/23
Orion 50.82 1.58 3.21% 16.56% Jan/23
Pfizer 26.47 0.47 1.81% -6.57% Jan/23
Philips 25.62 0.13 0.51% 21.25% Jan/23
Recordati 55.80 0.05 0.09% 11.73% Jan/23
Regeneron Pharmaceuticals 694.78 15.69 2.31% -26.73% Jan/23
Roche Holding 274.40 0.60 0.22% 11.93% Jan/23
Sanofi 99.89 1.04 1.05% 7.93% Jan/23
UCB 183.80 0.70 0.38% 111.65% Jan/23

Indexes Price Day Year Date
GB100 8561 20.07 0.23% 13.70% Jan/24
EU600 530 0 0% 10.83% Jan/24

AstraZeneca traded at 11,046.00 this Thursday January 23rd, increasing 6.00 or 0.05 percent since the previous trading session. Looking back, over the last four weeks, AstraZeneca gained 5.85 percent. Over the last 12 months, its price rose by 5.66 percent. Looking ahead, we forecast AstraZeneca to be priced at 11,037.61 by the end of this quarter and at 10,846.67 in one year, according to Trading Economics global macro models projections and analysts expectations.

AstraZeneca PLC is a biopharmaceutical company. It focuses on discovery and development of products, which are then manufactured, marketed and sold. It focuses on three main therapy areas: Oncology, Cardiovascular, Renal & Metabolic (CVRM) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVRM, it is expanding its portfolio into the cardiovascular-renal area with roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). It has approximately 38 projects in Phase I, including 26 new molecular entities (NMEs), and 12 oncology combination projects. It has approximately 43 projects in Phase II, including 25 NMEs; six additional indications for projects that have reached phase II, and 12 oncology combination projects. It has approximately 22 projects in late-stage development, either in Phase III/pivotal Phase II studies or under regulatory review.